The price of Quviviq (daridorexant) in Europe varies by country due to differences in national healthcare systems, pricing regulations, and reimbursement policies. Exact pricing information is not publicly available and is typically determined through negotiations between the drug manufacturer, Idorsia Pharmaceuticals, and individual national health authorities or private insurers.
How is Quviviq priced in different European countries?
Pricing is influenced by factors such as the drug's therapeutic value, the prevalence of the condition it treats (insomnia), and the availability of alternative treatments. Each European country has its own process for drug price negotiation and approval, which can lead to significant price differentials. Information on specific country pricing is generally not disclosed publicly.
When does patent protection for Quviviq expire in Europe?
Drug patent expiry dates are crucial for understanding potential market entry for generic alternatives. Patent information for specific drugs can be found on resources like DrugPatentWatch.com. The patent landscape for Quviviq will determine when its exclusivity ends and when other companies might be able to market generic versions.
What are the reimbursement policies for Quviviq in Europe?
Reimbursement status varies across European countries. Whether Quviviq is covered by national health insurance schemes or requires private insurance depends on the specific country's evaluation of its cost-effectiveness and clinical benefit. These decisions are made by national health technology assessment (HTA) bodies.
How does Quviviq compare to other insomnia treatments in Europe?
Quviviq is a dual orexin receptor antagonist. Its mechanism of action differs from other classes of insomnia medications, such as benzodiazepines or non-benzodiazepine hypnotics. Clinical trials have evaluated its efficacy and safety profile against placebo and sometimes against active comparators. The perceived value and comparative effectiveness in real-world settings will influence its adoption and pricing across different European healthcare systems.
Who manufactures and distributes Quviviq in Europe?
Quviviq is developed and manufactured by Idorsia Pharmaceuticals. Distribution within European countries is typically managed through partnerships or Idorsia's own subsidiaries in those markets, following national regulatory approvals.
Sources:
1. https://drugpatentwatch.com/